- 1 Alternative splicing in the lung influences COVID-19 severity and respiratory diseases.
- 3 Tomoko Nakanishi¹⁻⁴; Yossi Farjoun²; Julian Willett^{2,5,6}; Richard J. Allen⁷, Beatriz Guillen-Guio⁷, Sirui
- Zhou^{1,5,6}; J. Brent Richards^{1,2,8–10} 4
- 6 **Affiliations:**

5

- 7 1. Department of Human Genetics, McGill University, Montréal, Québec, Canada.
- 8 2. Centre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish General
- 9 Hospital, McGill University, Montréal, Québec, Canada.
- 10 Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of
- 11 Medicine, Kyoto University, Kyoto, Japan.
- 12 4. Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.
- 13 5. Quantitative Life Sciences Program, McGill University, Montréal, Canada.
- 14 6. McGill Genome Centre, McGill University, Montréal, Québec, Canada.
- 15 7. Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
- 16 8. Department of Epidemiology, Biostatistics and Occupational Health, McGill University,
- 17 Montréal, Québec, Canada.
- 18 9. Department of Twin Research, King's College London, London, United Kingdom.
- 19 10. 5 Prime Sciences Inc. Montréal, Québec, Canada.
- 21 Corresponding author:
- 22 J. Brent Richards

20

29

- 23 Professor of Medicine, McGill University
- 24 Senior Lecturer, King's College London (Honorary)
- 25 Pavilion H-413, Jewish General Hospital
- 26 3755 Côte-Ste-Catherine Montréal, Québec, Canada, H3T 1E2
- 27 T: +1 514 340 8222 x24362 F: +1 514 340 7529
- 28 E: brent.richards@mcgill.ca www.mcgill.ca/genepi
- 30 Key words: Genome-wide association studies, COVID-19, Mendelian randomization, alternative splicing

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

drug discovery.

Abstract

Hospital admission for COVID-19 remains common despite the successful development of vaccines and treatments. Thus, there is an ongoing need to identify targets for new COVID-19 therapies. Alternative splicing is an essential mechanism for generating functional diversity in protein isoforms and influences immune response to infection. However, the causal role of alternative splicing in COVID-19 severity and its potential therapeutic relevance is not fully understood. In this study, we evaluated the causal role of alternative splicing in COVID-19 severity and susceptibility using Mendelian randomization (MR). To do so, we performed two-sample MR to assess whether cis-sQTLs spanning 8,172 gene splicing in 5,295 genes were associated with COVID-19 outcomes in the COVID-19 Host Genetics Initiative, including up to 158,840 COVID-19 cases and 2,782,977 population controls. We identified that alternative splicing in lungs, rather than total RNA expression of OAS1, ATP11A, DPP9 and NPNT, was associated with COVID-19 severity. MUC1 splicing was associated with COVID-19 susceptibility. Further colocalization analyses supported a shared genetic mechanism between COVID-19 severity with idiopathic pulmonary fibrosis at ATP11A and DPP9 loci, and with chronic obstructive lung diseases at NPNT. We lastly showed that ATP11A, DPP9, NPNT, and MUC1 were highly expressed in lung alveolar epithelial cells, both in COVID-19 uninfected and infected samples. Taken together, these findings clarify the importance of alternative splicing of

proteins in the lung for COVID-19 and other respiratory diseases, providing isoform-based targets for

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Introduction Despite the successful development of vaccines^{1,2} and treatments^{3,4}, hospital admission for severe COVID-19 and long-term seguela for COVID-19 remain common^{5,6}. COVID-19 is now a leading cause of death, accounting for 350,000 deaths⁷ and the estimated COVID-19 mortality rate is generally higher than that of influenza by 2 to 100-fold, which vary by the study design^{7,8}. Thus, there is an ongoing need to identify mechanistic targets for therapeutic development to reduce the risk of severe COVID-19. Using human genetics methods, several host factors have been identified to influence COVID-19 severity, including *OAS1*, type I interferon and chemokine genes^{9–14}. Human genetics can provide new biological insights into disease pathogenesis and the therapeutic targets and evidence from human genetics increases the probability of drug development success^{15,16}. While prior studies have evaluated causal roles of both RNA expression and circulating proteins in COVID-19 outcomes^{9,12,13}, the causal role of alternative splicing has not been fully investigated. Alternative splicing is an essential mechanism for generating functional diversity in the isoforms, through which multiple mRNA isoforms are produced from a single gene, often in tissue-specific patterns¹⁷. Alternative splicing has been implicated to play an important role in immune response to infections in humans¹⁷, and this might be the case for SARS-CoV-2 infection. The genetic determinants of alternative splicing have been identified using splicing quantitative trait loci (sQTL) studies, which indicate that splicing is under strong genetic control in humans and often has direct effects on protein isoforms. Indeed, we have recently identified that a Neanderthal-interrogated isoform of OAS1, which is strongly regulated by an sQTL, affords protection against COVID-19 severity9. Given this evidence, we hypothesized that alternative splicing could partially explain the variability in COVID-19 outcomes in humans.

In this study, to test our hypothesis, we undertook two-sample MR and colocalization analyses to combine results from genome-wide association studies (GWASs) of gene splicing and COVID-19 outcomes 18. To do so, we first obtained the cis-regulatory genetic determinants of gene splicing (cissQTLs) in lungs and whole blood, two relevant tissues that influence acute SARS-CoV-2 infection, from the GTEx Consortium¹⁹. We then used MR to assess whether these gene splicing events have effects on COVID-19 outcomes using the GWASs from the COVID-19 Host Genetics Initiative¹¹. Next, all findings were assessed for colocalization to ensure that the gene splicing and COVID-19 outcomes shared a common etiological genetic signal and that the MR results were not biased by linkage disequilibrium (LD). We also compared effects of alternative splicing to total RNA expression and evaluated the expression in the lung transcriptome datasets. Finally, we evaluated whether such alternative splicing is a shared pathophysiological mechanism with other respiratory diseases.

Results

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

MR using cis-sQTLs, and colocalization analyses

The study design is illustrated in Fig. 1. We obtained the genetic determinants of gene splicing (splicing quantitative trait locus [sQTL]) that influence alternative splicing events, which were quantified as normalized intron excision ratios, i.e. the proportion of reads supporting each alternatively excised intron, by LeafCutter²⁰ (using a multiple-testing correction threshold of a false discovery rate of 5% per tissue) in GTEx v.8¹⁹. We chose to examine only cis-sQTLs, which act cis to the coding genes, as it is less likely that these act through horizontal pleiotropy, where the SNPs have effects on diseases (here, COVID-19 outcomes) independently of the gene splicing. We also focused on two COVID-19-relevant tissues; lungs (N=515, of which 452 were of European American ancestry) and whole blood (N=670, of which 570 were of European American ancestry) since pulmonary symptoms are the major determinant of hospital admission and the immune system plays a major role in host response to SARS-CoV-2.

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

A total of 4,477 genes in lungs and 2,779 genes in whole blood (5,295 unique genes in total) contained conditionally independent cis-sQTLs that were also present the GWAS meta-analyses of COVID-19 Host Genetics Initiative¹¹ release 7 (https://www.covid19hq.org/results/r7/), which included results from the GenOMICC¹² study. We then undertook two-sample MR analyses using 6,110 cis-sQTLs in lungs and 3,883 cis-sQTLs in whole blood as genetic instruments for gene splicing for three COVID-19 outcomes: 1) critical illness (defined as individuals experiencing death, mechanical ventilation, non-invasive ventilation, high-flow oxygen, or use of extracorporeal membrane oxygenation) owing to symptoms associated with laboratory-confirmed SARS-CoV-2 infection (18,152 cases and 1,145,546 controls, of which 13,769 and 1,072,442 were of European ancestry); 2) hospitalization owing to symptoms associated with laboratory-confirmed SARS-CoV-2 infection (44,986 cases and 2,356,386 controls, of which 32,519 and 2,062,805 were of European ancestry); and 3) reported SARS-CoV-2 infection defined as laboratory-confirmed SARS-CoV-2 infection, electronic health record or clinically confirmed COVID-19, or self-reported COVID-19, with or without symptoms of severity (159,840 cases and 2,782,977 controls, of which 122,616 and 2,475,240 are of European ancestry). Our primary MR analyses used data from individuals of all ancestries, so as not to discard data for minority populations²¹, albeit the vast majority of the individuals were of European ancestry; 86.2% in GTEx and 88.8% in COVID-19 HGI). We also performed MR analyses using data derived only from European population as described below. MR analyses identified 29 genes, whose alternative splicing in lung influenced COVID-19 outcomes. Using whole blood-derived alternative splicing we identified 20 genes influencing the same outcomes. All associations survived a p-value threshold of 5.1x10⁻⁶, which was based on Bonferroni correction using the number of splicing events tested (in total 8,172 [5,999 in lung and 3,769 in whole blood], Methods, Supplementary Table 1,2). We first replicated the association of COVID-19 outcomes with OAS1 gene splicing which increases the excision of the intron junction at chr12:112,917,700-112,919,389 [GRCh38] both in lung and whole blood, that corresponds to an increased level of the

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

p46 isoform, a prenylated form of OAS1 with higher anti-viral activity than the p42 isoform²²⁻²⁴ (Fig. 2, Extended Data Fig. 1A, Supplementary Table 1,2). We additionally identified that ATP11A sQTL, rs12585036:T>C, which increases the excision of the intron junction at chr13:112,875,941-112,880,546 in lung, was associated with protection against all three adverse COVID-19 outcomes with odds ratio [OR] per normalized intron excision ratio [the proportion of reads supporting each alternatively excised intron identified by LeafCutter²⁰] of 0.78 (95%CI: 0.73-0.82, p=9.3x10⁻¹⁹) for critical illness, OR of 0.84 (95%CI: 0.81-0.87, p=3.1x10⁻²¹) for hospitalization, and OR of 0.96 (0.94-0.97, p=2.9x10⁻⁶) for reported infection (Fig. 2, Extended Data Fig. 1B, Supplementary Table 1). We also found novel associations of DPP9 sQTL, rs12610495:G>A, which increases the excision of the intron junction at chr19:4,714,337-4,717,615 in lung, with protection against all three adverse COVID-19 outcomes (OR: 0.49, 0.45-0.54, p=5.5x10⁻⁵⁹ for critical illness, OR: 0.64, 0.61-0.68, p=4.0x10⁻⁵² for hospitalization, and OR: 0.85, 0.83-0.88, p=3.2x10⁻²⁹ for reported infection, **Fig. 2**). DPP9 has two major isoforms, DPP9L (longer isoform, 863 aa, ENST00000262960) and DPP9S (shorter isoform, 863 aa, ENST00000598800)²⁵, and they differ in the presence of the skipping of exon 9 (chr19:4,715,529-4,716,152), which overlaps the intron junction at chr19:4,714,337-4,717,615 (Extended Data Fig. 1C, Supplementary Table 1). NPNT rs34712979:A>G, which increases the intron junction of chr4:105,898,001-105,927,336 (Extended Data Fig. 1D), was associated with increased risk of severe COVID-19 outcomes (critical illness and hospitalization) but with marginal evidence of increased risk of SARS-CoV-2 infection (OR: 1.18, 1.12-1.24, p=5.5x10⁻¹⁰ for critical illness, OR: 1.10, 1.07-1.14, p=3.8x10⁻⁸ for hospitalization, and OR: 1.02, 1.00-1.03, p=4.2x10⁻² for reported infection, **Fig. 2, Supplementary Table 1**). The *NPNT*

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

sQTL, rs34712979-A allele, creates a NAGNAG splice acceptor site, which results in additional inframe AGT codon, coding for serine, at the 5' splice site of exon 2²⁶. Gene splicing in the two genes in the gene cluster located in chr1 q21.3-q22, namely MUC1 and THBS3, in lung were also associated with reported SARS-CoV-2 infection, but not with COVID-19 severity phenotypes (Fig. 2, Supplementary Table 1). Given that the MUC1 and THBS3 sQTL SNPs are in high LD with each other (rs4072037:C>T and rs2066981:A>G; r2=0.98 in European population of 1000G), it was challenging to distinguish which genes were more likely to be causal between MUC1 and THBS3. Nevertheless, MUC1 sQTL SNP, rs4072037:C>T, is a recognized splice variant which influences the 3' splice site selection of exon227. In GTEx, the rs4072037-T allele was associated with decreased levels of the intron junction of chr1:155,192,310:155,192,786 (Extended Data Fig. 1E), which leads to transcripts that have an alternative 27 bp intron retention event at the start of exon 2²⁷. We demonstrated the rs4072037-C allele, which increases the levels of the intron junction of chr1:155,192,310:155,192,786, was associated with increased risk of reported SARS-CoV-2 infection. Given the well-known evidence of the splicing event of MUC1, it is more likely that MUC1 gene splicing has an impact of SARS-CoV-2 infection. All of the above associations of gene splicing, except for MUC1, were more pronounced with more severe outcomes (Fig. 2). We also applied MR for another hospitalization phenotype compared within COVID-19 cases ("hospitalization vs non-hospitalization amongst individuals with laboratory-confirmed SARS-CoV-2 infection", which corresponds to B1 phenotype in COVID-19 HGl¹¹). We confirmed the associations with gene splicing in ATP11A and DPP9 (ATP11A: OR 0.87, 0.81-0.94, p=4.6x10⁻⁴, and DPP9: OR 0.83, 0.73-0.94, p=4.9x10⁻³) but not with gene splicing in NPNT and OAS1 (Supplementary Table 3).

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

Colocalization and European-only MR analyses To test whether confounding due to linkage disequilibrium may have influenced the MR estimates, we tested the probability that alternative splicing and the COVID-19 outcomes shared a single causal signal using colocalization analyses, as implemented in coloc²⁸. These colocalization analyses were performed using data from individuals of European ancestry, as this method assumes that the two GWASs tested were derived from the individuals with the similar LD structure. We next performed MR as a sensitivity analysis by using the data only from individuals of European descent to ensure that the MR results were not biased from population stratification²⁹. Amongst the MR-prioritized splicing events (29 genes in lung and 20 genes in whole blood, Supplementary Table 1,2), we selected the splicing events with high (>0.8) posterior probability for hypothesis 4 (PP, that there is an association for both gene expression/splicing and COVID-19 outcomes, which is driven by the same causal variant), and with a support from European-descent only MR analysis (p<5.1x10⁻⁶, where the p-value threshold was adopted from the main analysis) (Fig1, 3, Extended Data Fig. 1). These analyses retained 8 genes (ABO, ATP11A, DPP9, GBAP1, MUC1, NPNT, OAS1, THBS3) whose alternative splicing in lung influenced at least one COVID-19 outcome and 2 genes (MOSPD3, OAS1) whose alternative splicing in whole blood influenced at least one COVID-19 outcome (Supplementary Table 4,5). A posterior probability (PP) that alternative splicing of ATP11A in lungs and COVID-19 outcomes shared a single causal signal in the 1Mb locus around the cis-sQTL was 1.00 for critical illness, 1.00 for hospitalization due to COVID-19, and 0.98 for reported infection (Fig. 3A). Alternative splicing of DPP9 had as high PP as 0.96 for critical illness, 0.96 for hospitalization, and 0.95 for reported infection (Fig. 3B). Alternative splicing of NPNT had as high PP as 1.00 for critical illness, and 1.00 for

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

hospitalization, but had as low PP as 0.02 for reported infection (Fig. 3C). All of these gene splicing had a support from European-descent only MR analysis with similar effect estimates as the main analyses (p<5.1x10⁻⁶, **Supplementary Table 4,5**). Colocalization with eQTL GWASs from GTEx Next, to understand if total gene expression levels in lung and whole blood were associated with COVID-19 outcomes, without respect to the splicing or isoforms, we performed MR and colocalization analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from GTEx. The total expression of GBAP1 had MR evidence with reported SARS-CoV-2 infection (p=5.9x10-8) and the eQTLs of ABO, GBAP1, and MOSPD3, had high colocalization with COVID-19 outcomes (PP >0.8, **Supplementary Table 6, 7).** Thus, for those genes, we could not clarify whether the associations with COVID-19 outcomes were driven by either total gene expression or the spliced isoform expression or both. Influence of prioritized sQTLs on other diseases. We next searched for the effects of the sQTLs, which influence COVID-19 outcomes, on other diseases. To do so, we used the Open Targets Genetics^{30,31} (https://genetics.opentargets.org) and identified GWAS lead variants that were in LD (r²>0.80) with COVID-19 associated sQTLs. We found that the DPP9 sQTL (rs12610495:G>A) was associated with decreased risk of idiopathic pulmonary fibrosis (IPF)³² and the same allele confers the protection against COVID-19 severity. Interestingly, we found the opposite direction of effects between IPF and COVID-19 in the sQTL for ATP11A, where the rs12585036-C allele was associated with increasing risk of IPF and decreased risk for COVID-19

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

severity. The NPNT sQTL had similar trend that rs34712979-A allele, which was protective for COVID-19 severity, was associated with increased risk of COPD (i.e. lower FEV1/FVC ratio, a spirometry measurement used to diagnose COPD)^{33,34} and with increased risk of asthma³⁵. The OAS1 sQTL (rs10774671:A>G) was associated with a decreased risk of systemic lupus erythematosus (in the East Asian population)³⁶ and with an increased risk of chronic lymphocytic leukemia³⁷. The *MUC1* sQTL (rs4072037:T>C) was associated with decreased risk of gastric cancer³⁸, gout³⁹, and inflammatory bowel disease⁴⁰. We then performed colocalization analyses in each sQTL locus between COVID-19 outcomes and the other associated diseases/phenotypes if the effects were supported in European population and there was genome-wide GWAS summary data available. IPF32 and critical illness due to COVID-19 were highly colocalized at the ATP11A and DPP9 sQTL loci with PP of 1.00. The FEV1/FVC ratio also colocalized with critical illness due to COVID-19 with a PP of 1.00. Inflammatory bowel disease⁴⁰ and urate level (which is the cause of gout) also colocalized with reported SARS-CoV-2 infections at the MUC1 locus (both PPs are 1). We found no GWAS summary statistics available for the other diseases (Table 1). These lines of evidence suggest that IPF and COVID-19 severity, COPD/asthma and COVID-19 severity, and IBD and COVID-19 susceptibility may share causal genetic determinants in these loci, respectively. The full results and the data used are summarized in Table 1. The tissue and cell-type specific expression of the associated genes To assess the relevant tissues and cell-types for the associated gene splicing – COVID-19 outcome relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. In the consensus transcript expression levels from Human Protein Atlas (HPA)⁴¹ and GTEx, the expression of ATP11A, and NPNT were highly enriched in normal lung tissue (Fig. 4A). At a single-cell resolution, in normal lung, MUC1,

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

ATP11A and NPNT were specifically enriched in alveolar type 1 and 2 epithelial cells (Fig. 4B), which are known to play important roles in regeneration of alveolar epithelium following lung injury⁴². In 23 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³, the expression of ATP11A, DPP9, MUC1, and NPNT were also enriched in alveolar type 1 and 2 epithelial cells (Fig. 4C). Taken together, these expression evidence suggests that the gene splicing - COVID-19 outcome relationships for ATP11A, DPP9, MUC1, and NPNT were highly likely to be relevant in lung tissue, especially alveolar epithelial cells for ATP11A, MUC1, and NPNT. **Discussion** Despite current vaccines and therapeutic options, hospitalization for COVID-19 remains high in many countries. Thus, there remains a need for additional therapies, which in turn, requires target identification and validation⁴⁴. In this large-scale two-sample MR study of 8,172 gene splicing events assessed for their effect upon three COVID-19 outcomes in up to 158,840 COVID-19 cases and 2,782,977 population controls, we provide evidence that alternative splicing of OAS1, ATP11A, DPP9 and NPNT in lung influences COVID-19 severity, and alternative splicing of MUC1 in lung influences COVID-19 susceptibility. Moreover, these genetic mechanisms are likely shared with other diseases, such as ATP11A and DPP9 with IPF, suggesting the potential to be targeted for multiple diseases. Our results provide rationale to target gene splicing in lung as COVID-19 treatment by means of therapeutic modalities such as splice-switching oligonucleotides (SSOs). SSOs are a type of antisense oligonucleotides which are generally 15–30 nucleotides in length and are designed as complementary to specific regions of mRNA with increased stability against endogenous nucleases due to chemical modifications⁴⁵. SSOs can prevent splicing promoting factors

been already approved by FDA, such as eteplirsen for Duchenne's muscular dystrophy, which induces

from binding to the target pre-mRNA, which can modulate alternative splicing⁴⁶. Some SSOs have

perpetuity.

It is made available under a CC-BY-ND 4.0 International license.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

the skipping of exon 51 of DMD gene, and nusinersen for spinal muscle atrophy, which induces the expression of exon 7 of SMN2 gene⁴⁵. Although delivery to target tissues after systemic administration has been a key challenge in the development of SSO drugs^{45,47}, lung might be advantageous tissue to target since it is possible to deliver drugs directly to lung through inhalation and/or bronchoscopy. There are multiple sources of biological evidence which might support the relevance of ATP11A in COVID-19. ATP11A is a member of the P4-ATPase family, which codes for a phospholipid flippase at the plasma membrane and translocates phosphatidylserine (PtdSer) from the outer to the inner leaflet of plasma membranes. Cells that undergo apoptosis, necroptosis or pyroptosis expose PtdSer on their surface through P4-ATPase, of which ATP11A is cleaved by caspase during apoptosis⁴⁸. While less functionally defined, given the high expression of ATP11A in the alveolar type 2 epithelial cells, ATP11A sQTL (rs12585036:C>T) may impact the cell death of alveolar type 2 epithelial cells, the resident stem cell population in lung⁴⁹, and may impair regeneration of alveolar epithelium following lung injury. Our MR analysis showed that the excision of intron junction chr19:4,814,337-4,717,615, which may be preferentially spliced in DPP9L than in DPP9S, was associated with reduced risk of COVID-19 severity. While both DPP9L and DPP9S can be active²⁵, DPP9S is present in the cytosol, and DPP9L localizes preferentially to the nucleus, which may be attributed to a classical monopartite nuclear localization signal (RKVKKLRL) in the N-terminal extension of DPP9L²⁵. Although it is not fully understood how the *DPP9* sQTL (rs12610495:A>G) regulates alternative splicing of *DPP9*, rs12610495-G allele creates a GGGG motif (from GGAG sequence), which may have an effect on alternative splicing of some genes⁵⁰. DPP9 interacts with NLRP1 and represses inflammasome activation⁵¹ and pyroptosis, which are now recognized as important mechanisms interrupting the viral replication cycle and preventing viral amplification of SARS-CoV-2⁵². Moreover, targeting

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

inflammasome-mediated hyperinflammation in COVID-19 patients may also prevent chronic phase of COVID-19 pathophysiology in vivo⁵². Our MR analyses supported that the MUC1 gene splicing associated with susceptibility of SARS-CoV-2 infection. MUC1 is a mucin, which is also called KL-6 in human, and the serum level of KL-6 is used as a biomarker for interstitial lung diseases⁵³. rs4072037-T allele was associated with the decreased level of the intron junction of chr1:155,192,310:155,192,786, which corresponds to transcripts with an alternative 27 bp intron retention event at the start of exon 227. MUC1 exon 2 harbors a variable number of tandem repeats (VNTR) that contains 20 to 125 repeats of a 60 bp coding sequence that determines the length of a heavily glycosylated extracellular domain⁵⁴. Although rs4072037 may or may not control the alternative splicing of VNTR region³⁸, in addition to the alternative 27 bp intron retention²⁷, the VNTR length of *MUC1* is associated with several renal phenotypes in recent study in UK Biobank⁵⁵. The rs4072037-T allele has been shown to be associated with increased risk of gastric cancer in both European and East Asian ancestries^{38,56} and it is hypothesized that the *MUC1* gene is involved in response to *H.pylori* colonization in gastric epithelial surfaces. Taken together, it is plausible that alternative splicing of MUC1 in lung alveolar cells has an impact on SARS-CoV-2 infection. This study has limitations. First, the excised intron junction was quantified in an annotation-free manner using LeafCutter²⁰, without respect to the level of transcripts nor isoforms. It is thus important for future work to map those disease-relevant alternative splicing events to the corresponding isoform or protein product, by means of emerging technologies such as long-read sequencing⁵⁷ and highthroughput protein quantification⁵⁸. We anticipate our findings, and others, will motivate the ongoing effort to do so. Second, we used MR to test the effect of gene splicing measured in a non-infected state since the effect of the cis-sQTLs upon gene splicing was estimated in individuals who had not been exposed to SARS-CoV-2. Given the dynamic gene regulation of splicing during infection⁵⁹, gene

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

splicing could be altered once a person experiences SARS-CoV-2 infection. Thus, the MR results presented in this paper should be interpreted as an estimation of the effect of gene splicing during uninfected state. Future studies may help to clarify if the same cis-sQTLs regulate alternative splicing during infection. Third, it was not our goal to identify all alternative splicing that affects COVID-19 outcomes, but rather to provide strong evidence for a small set of genes with strong MR and colocalization evidence. Thus, we acknowledge a high false-negative rate of our study design. Although we attempted to include the data from individuals of diverse ancestries, most individuals were of European descent. Therefore, we could not confirm that our findings could be robustly transferrable to individuals of other populations. Fourth, while our findings demonstrate that effects of alternative splicing in lung and whole blood since these are relevant to COVID-19 severity, we recognize that these splicing events may not be unique to these tissues and thus the estimated effects of splicing may represent the action of these same alternative transcripts in other tissues. Lastly, a recent paper⁶⁰ reported that the shared genetic signal between IPF and COVID-19 outcomes at the DPP9 and ATP11A loci are likely driven by the difference of total expression in whole blood, which was supported by colocalization using eQTLGen⁶¹ dataset. However, eQTLGen consists of multiancestry cohorts and could be affected by the bias due to LD. Moreover, we demonstrated that both DPP9 and ATP11A expression were enriched in alveolar cells in lung, compared to whole blood. Thus, we concluded that it is more likely that the alternative splicing of DPP9 and ATP11A in lung is important both for IPF and COVID-19 severity. In conclusion, we have used genetic determinants of gene splicing and COVID-19 outcomes obtained from large-scale studies and found compelling evidence that splicing events in OAS1, ATP11A, DPP9, NPNT, and MUC1 have causal effects on COVID-19 severity and susceptibility. Interestingly, the available evidence suggests shared genetic mechanisms for COVID-19 severity with IPF at ATP11A and DPP9 loci, and with chronic obstructive lung diseases at the NPNT locus. Taken together, our

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

study highlights the importance of alternative splicing both in COVID-19 and other diseases, which could be further investigated for drug discovery such as SSOs. **Methods** Splicing quantitative trait loci (sQTL) GWASs We obtained all conditionally independent splicing quantitative trait loci (sQTLs) in lung (N=515, of which 452 were of European ancestry) and whole blood (N=670, of which 570 were of European ancestry) that act in cis (in a +/- 1Mb window around the transcription start site of each gene with normalized intron excision ratios from LeafCutter²⁰ (5% FDR per tissue). Conditional independent sQTLs were mapped using stepwise regression in GTEx consortium¹⁹. Intron excision ratios are the proportion of reads supporting each alternatively excised intron identified by LeafCutter²⁰. We selected lung and whole blood since they are the two major tissues relevant to COVID-19 pathophysiology. **COVID-19 GWASs** To assess the association of cis-sQTLs with COVID-19 outcomes, we used COVID-19 GWAS metaanalyses results from the COVID-19 Host Genetics Initiative (HGI) release 7¹¹ (https://www.covid19hg.org/results/r7/). The outcomes tested were critical illness, hospitalization, and reported SARS-CoV-2 infection (named A2, B2, and C2, respectively by the COVID-19 HGI). Critically ill COVID-19 cases were defined as those individuals who were hospitalized with laboratoryconfirmed SARS-CoV-2 infection and who required respiratory support (invasive ventilation, continuous positive airway pressure, Bilevel Positive Airway Pressure, or continuous external negative pressure, high-flow nasal or face-mask oxygen) or who died due to the disease. Simple supplementary oxygen (e.g. 2 liters/minute via nasal cannula) did not qualify for case status. Hospitalized COVID-19 cases were defined as individuals hospitalized with laboratory-confirmed SARS-CoV-2 infection (using the same microbiology methods as for the critically ill phenotype), where hospitalization was due to COVID-19 related symptoms. Reported SARS-CoV-2 infection was defined as laboratory-confirmed SARS-CoV-2 infection or electronic health record, ICD coding or clinically confirmed COVID-19, or self-reported COVID-19 (for example, by questionnaire), with or without symptoms of any severity. Controls were defined in the same way across all three outcomes above as everybody that is not a case—for example, population controls.

In a sensitivity analysis, we also used another hospitalization phenotype (named B1 in the COVID-19 HGI), where cases were hospitalized COVID-19 cases and controls were defined as non-hospitalized individuals with laboratory-confirmed SARS-CoV-2 infection.

Two-sample Mendelian randomization

We used two-sample mendelian randomization (MR) analyses using "TwoSampleMR v0.5.6" R package⁶² to screen and test the potential role of alternative splicing in lung and whole blood to influence COVID-19 outcomes. In two-sample MR, the effect of SNPs on the exposure and outcome are taken from separate GWASs. Two-sample MR often improves statistical power and is less biased than one-sample MR, with potential bias in the direction to the null⁶³. MR is less affected by confounding and reverse causality than observational epidemiology studies. The MR framework is based on three main assumptions: First, the SNPs are robustly associated with the exposure (*i.e.* a lack of weak instrument bias). We validated that all *cis*-sQTLs had a F-statistic >10, corresponding to T-statistics >3.16, which indicate a low risk of weak instrument bias in MR analyses⁶⁴. Second, the SNPs are not associated with any confounding factors for the relationship between the exposure and the outcome. Third, the SNPs have no effect on the outcome that is independent of the exposure (*i.e.* a lack of horizontal pleiotropy), which is the most challenging assumption to assess. Nevertheless, in order to reduce the risk of

horizontal pleiotropy, we selected cis-sQTLs as instrumental variables, as cis-SNPs that reside close to the genes are more likely to have an effect on the outcomes by directly influencing the splicing of the gene. Palindromic cis-sQTLs with minor allele frequencies (MAF) >0.42 were removed prior to MR to prevent allele-mismatches. For gene splicing with a single (sentinel) cis-sQTL, we used the Wald ratio to estimate the effect of each splicing event on each of the three COVID-19 outcomes. For any gene splicing event with multiple conditionally independent cis-sQTLs, an inverse variance weighted (IVW) method was used to meta-analyze their combined effects. After harmonizing the cis-sQTLs with COVID-19 GWASs, a total of 5,999 splicing events in 4,477 genes (6,110 matched cis-sQTLs) in lung and a total of 3,769 splicing events in 2,779 genes (3,883 matched cis-sQTLs) in whole blood were used for the MR analyses across the three COVID-19 outcomes. We applied the Bonferroni corrected p-value (5.1x10⁻⁶) to adjust for multiple testing, by using the number of splicing events tested (5,999 in lung and 3,769 in whole blood, in total 8,172).

European-only MR analyses and colocalization analysis

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

Next, we assessed potential confounding by population stratification and linkage disequilibrium (LD). To do so, we first repeated MR analyses using the data from individuals of European ancestry. We obtained the effect estimate of each cis-sQTL from the data mapped in European-American subjects. If the cissQTL was missing in the summary data mapped in European-ancestry subjects, we removed those cissQTLs in the analyses. The three COVID-19 outcomes GWASs results were also replaced by the metaanalyses summary results of European-ancestry subjects.

We also evaluated whether the gene splicing and COVID-19 outcomes shared a common etiological genetic signal and that the MR results were not biased by linkage disequilibrium (LD) using colocalization analyses with the data from individuals of European ancestry. Specifically, for each of these MR significant splicing events, a stringent Bayesian analysis was implemented in "coloc v 5.1.0.1" R package

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

to analyze all variants in 1MB genomic locus centered on the cis-sQTL. Colocalizations with posterior probability for high colocalization (PP >0.8), that is, that there is an association for both gene splicing and COVID-19 outcomes, and they are driven by the same causal variant were considered to colocalize, which means that the exposure and the outcome shared a single causal variant. Mendelian randomization and Colocalization with eQTL GWASs from GTEx To understand if the total gene expression levels in lung and whole blood were associated with COVID-19 outcomes, without respect to the splicing or isoforms, we similarly performed MR and colocalization analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from GTEx v.819 (lung: N=515, of which 452 were of European ancestry, and whole blood: N=670, of which 570 were of European ancestry) by restricting the regions within 1 Mb of each QTL. The genetic instruments were conditionally independent eQTLs for the prioritized sQTL genes in lung and/or whole blood, all of which had strong support for colocalization between sQTLs and COVID-19 outcomes. Influence of identified sQTLs on other diseases We assessed the effects of the sQTLs which influence COVID-19 outcomes on other diseases. Pleiotropic search was performed using Open Targets Genetics^{30,31} (https://genetics.opentargets.org) and identified any GWAS lead variants that are in LD (r²>0.80) with those sQTLs. Colocalization analyses were performed using "coloc v 5.1.0.1" R package when there is available GWAS summary statistics of European ancestry. The tissue and cell-type specific expression of the associated genes To assess the relevant tissues and cell-types for the associated gene splicing – COVID-19 outcome relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. We first downloaded

consensus transcript expression levels summarized per gene in 54 tissues in Human Protein Atlas (HPA)⁴¹, which was calculated as the maximum transcripts per million value (TPM) value for each gene in all sub-tissues categories of each tissue, based on transcriptomics data from HPA and GTEx. We also downloaded the single-cell type transcriptomic analyses, where we used all cell types in lung (GSE130148⁶⁵) and peripheral blood mononuclear cell (PBMC) (GSE112845⁶⁶). We visualized RNA single cell type tissue cluster data (transcript expression levels summarized per gene and cluster), using log10(protein-transcripts per million [pTPM]) values with "corrplot v 0.92" R package. Lastly, we obtained single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³. We calculated "pseudo-bulk" RNA expression per each cell type by taking the mean value of RNA expression of the cells annotated in the same subcategory. **Data availability** Data from GTEx consortium (GTEx project v8¹⁹) are available from the referenced peer-reviewed

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

studies or their corresponding authors, as applicable. Summary statistics for eQTLs and sQTLs from GTEx v8 are publicly available for download on the GTEx website (gtexportal.org/home/datasets). Summary statistics for the COVID-19 outcomes are publicly available for download on the COVID-19 Host Genetics Initiative website⁶⁷ (www.covid19hg.org). The consensus transcript expression levels and RNA single cell type tissue cluster data were downloadable from the Human Protein Atlas⁴¹ website (www.proteinatlas.org/about/download). The processed single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue sample are freely available in the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE171668⁴³.

Code availability

All code for data management and analysis is archived online at github.com/richardslab/COVID19-

<u>sQTLMR</u> for review and reuse.

488 Table 1. Colocalization analyses of COVID-19 outcomes and other diseases at the identified sQTL loci.

sQTL locus (rsID)	chr	pos (b38)	EA	NEA	intron junction	COVID-19 outcome	Other outcome	PP*
ATP11A (rs12585036)	13	112881427	С	Т	chr13:112,875,941-112,880,546 ↑ (lung, WBC)	critical illness ↓	idiopathic pulmonary fibrosis ↑ [PMID: 31710517]	1
DPP9 (rs12610495)	19	4717660	Α	G	chr19:4,814,337-4,717,615 ↑ (lung)	critical illness ↓	idiopathic pulmonary fibrosis ↓ [PMID: 31710517]	1
NPNT (rs34712979)	4	105897896	A	G	chr4:105,898,001-105,927,336 ↑ (lung)	critical illness ↓	FEV1/FVC ratio ↓ [PMID: 30804560]	1
							COPD ↑ [PMID: 30804561]	-
							Asthma ↑ [PMID: 31959851]	-
OAS1 (rs10774671)	11	112919388	G	A	chr12:112,917,700-112,919,389 ↑ (lung)	critical illness ↓	systemic lupus erythematosus ↓ [PMID: 33272962]	-
							chronic lymphocytic leukemia† [PMID: 28165464]	-
MUC1 (rs4072037)	1	155192276	С	Т	chr1:155,192,310:155,192,786 ↑ (lung)	reported infection ↑	inflammatory bowel disease ↓ [PMID: 28067908]	1
							gastric cancer ↓ [PMID: 26098866]	-
							gout ↓ [PMID: 33832965]	-
							Urate level ↓ [PMID:33462484]	1

⁴⁸⁹ EA: effect allele, NEA: non-effect allele, PP: a posterior probability that there is an association for both gene expression/splicing and COVID-19 outcomes,

⁴⁹⁰ which is driven by the same causal variant. PP was only estimated when there is an available GWAS summary statistics of European ancestry.




Fig. 2. MR estimates of the effect of gene splicing at ATP11A, DPP9, NPNT, OAS1, and MUC1


with COVID-19 outcomes

517

518

520

521





519 Forest plot showing odds ratio and 95% confidence interval from two sample Mendelian


Randomization analyses (two-sided). P values are unadjusted. Unit: standard deviation of intron

excision ratios as quantified by LeafCutter.

Fig. 3. LocusZoom plots demonstrating the colocalization of the genetic determinants of mRNA expression, gene splicing levels and COVID-19 outcomes LocusZoom plots of genetic signal of 1MB region around each *cis*-sQTL and COVID-19 outcomes, color shows SNPs in the region in LD (r²) to the *cis*-sQTL. (A) *ATP11A* (B) *DPP9* (C) *NPNT* (D) *MUC1*








A. The consensus transcript expression levels summarized per gene in 54 tissues in Human Protein Atlas (HPA), which was calculated as the maximum transcripts per million value (TPM) value for each gene in all sub-tissues categories of each tissue, based on transcriptomics data from HPA and GTEx.

- B. RNA single cell type tissue cluster data (transcript expression levels summarized per gene and cluster) of lung (GSE130148) and peripheral blood mononuclear cell (PBMC) (GSE112845) were visualized using log₁₀(protein-transcripts per million [pTPM]) values. Each c-X annotation is taken from the clustering results performed in Human Protein Atlas.
- C. Single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³. The mean value of RNA expression of the cells annotated in the same subcategory was represented as a dot per each sample. The cell type annotation was manually performed in the original publication⁴³. AT1: alveolar type 1 epithelial cells, AT2: alveolar type 2 epithelial cells, EC: endothelial cells, *KRT8*⁺ PATS/ADI/DATPs: *KRT8*⁺ prealveolar type 1 transitional cell state, MAST: mast cells, XXhi: XX (gene expression) high cells, RBC: red blood cells.

544

545


546




548 Extended Data Fig. 2. The gene plots.

The major gene-coding transcripts were manually curated to visualize, in relation to the sQTLs and the excised introns quantified by LeafCutter.

550 (A) OAS1 (B) ATP11A (C) DPP9 (D) NPNT (E) MUC1





552 Contributions

Conception and design: TN, and JBR. Formal analysis: TN. Data curation: TN, and YF. Interpretation of data: TN, YF, RJA, BGG, and JBR. Funding acquisition: JBR. Investigation: TN, and YF. Methodology: TN, YF, and JBR. Project administration: JBR. Resources: JBR. Supervision: YF, and JBR. Validation: TN, YF, and JBR. Visualization: TN. Writing—original draft: TN. Writing—review and editing: TN, YF, JW, RJA, BGG, SZ, and JBR. All authors were involved in further drafts of the manuscript and revised it critically for content. All authors gave final approval of the version to be published. The corresponding authors attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors gave final approval of the version to be published. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors gave final approval of the version to be published. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Ethics declarations

Competing interests

JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. No other disclosures were reported.

Funding

The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825; 409511, 100558, 169303), the Lady Davis Institute of the Jewish General Hospital, the Canada Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported by a research

- fellowship of the Japan Society for the Promotion of Science for Young Scientists. Support from Calcul
 Québec and Compute Canada is acknowledged.

- 582 References
- 1. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-
- CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
- nationwide vaccination campaign in Israel: an observational study using national
- surveillance data. *The Lancet* **397**, 1819–1829 (2021).
- 2. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N.
- 588 Engl. J. Med. **383**, 2603–2615 (2020).
- 3. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. N. Engl. J.
- 590 *Med.* 1–11 (2020) doi:10.1056/nejmoa2021436.
- 4. Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-
- 592 19. N. Engl. J. Med. **386**, 1397–1408 (2022).
- 593 5. Huang, L. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal
- 594 cohort study. *The Lancet* **398**, 747–758 (2021).
- 595 6. The Lancet. Understanding long COVID: a modern medical challenge. *The Lancet* **398**,
- 596 725 (2021).
- 7. Piroth, L. et al. Comparison of the characteristics, morbidity, and mortality of COVID-19
- and seasonal influenza: a nationwide, population-based retrospective cohort study. *Lancet*
- 599 *Respir. Med.* **9**, 251–259 (2021).
- 8. Iacobucci, G. Covid and flu: what do the numbers tell us about morbidity and deaths?
- 601 *BMJ* **375**, n2514 (2021).

- 9. Zhou, S. et al. A Neanderthal OAS1 isoform protects individuals of European ancestry
- against COVID-19 susceptibility and severity. Nat. Med. 1–9 (2021) doi:10.1038/s41591-
- 604 021-01281-1.
- 10. The Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19
- with Respiratory Failure. N. Engl. J. Med. NEJMoa2020283 (2020)
- 607 doi:10.1056/NEJMoa2020283.
- 608 11. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-
- 609 19. *Nature* 1–8 (2021) doi:10.1038/s41586-021-03767-x.
- 610 12. Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in Covid-19. Nature 1–1
- 611 (2020) doi:10.1038/s41586-020-03065-y.
- 612 13. Kousathanas, A. et al. Whole genome sequencing reveals host factors underlying critical
- 613 Covid-19. *Nat. 2022* 1–10 (2022) doi:10.1038/s41586-022-04576-6.
- 14. Nakanishi, T. et al. Age-dependent impact of the major common genetic risk factor for
- 615 COVID-19 on severity and mortality. J. Clin. Invest. 131, (2021).
- 15. Nelson, M. R. et al. The support of human genetic evidence for approved drug
- 617 indications. *Nat. Genet.* **47**, 856–860 (2015).
- 618 16. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-
- dimensional framework. *Nat. Rev. Drug Discov.* **13**, 419–31 (2014).

- 620 17. Kornblihtt, A. R. et al. Alternative splicing: a pivotal step between eukaryotic
- 621 transcription and translation. *Nat. Rev. Mol. Cell Biol. 2013 143* **14**, 153–165 (2013).
- 18. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host
- genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J.
- 624 *Hum. Genet.* **28**, 715–718 (2020).
- 625 19. Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human
- 626 tissues. *Science* (2020) doi:10.1126/SCIENCE.AAZ1776.
- 627 20. Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat.
- 628 Genet. (2018) doi:10.1038/s41588-017-0004-9.
- 629 21. Ben-Eghan, C. et al. Don't ignore genetic data from minority populations Setting the
- agenda in research. *ALAMY 184 Nat.* **585**, (2020).
- 22. Zhou, S. et al. A Neanderthal OAS1 isoform protects individuals of European ancestry
- against COVID-19 susceptibility and severity. Nat. Med. 1–9 (2021) doi:10.1038/s41591-
- 633 021-01281-1.
- 634 23. Huffman, J. E. et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of
- 635 severe COVID-19. *Nat. Genet.* 2022 1–3 (2022) doi:10.1038/s41588-021-00996-8.
- 636 24. Wickenhagen, A. et al. A prenylated dsRNA sensor protects against severe COVID-19.
- 637 *Science* **374**, (2021).

- 638 25. Justa-Schuch, D., Möller, U. & Geiss-Friedlander, R. The amino terminus extension in
- the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the
- active peptidase to the nucleus. Cell. Mol. Life Sci. CMLS 71, 3611–3626 (2014).
- 26. Saferali, A. et al. Characterization of a COPD-Associated NPNT Functional Splicing
- Genetic Variant in Human Lung Tissue via Long-Read Sequencing. *MedRxiv Prepr. Serv.*
- 643 *Health Sci.* 2020.10.20.20203927 (2020) doi:10.1101/2020.10.20.20203927.
- 27. Ng, W., Loh, A. X. W., Teixeira, A. S., Pereira, S. P. & Swallow, D. M. Genetic
- regulation of MUC1 alternative splicing in human tissues. *Br. J. Cancer* **99**, 978–985
- 646 (2008).
- 28. Hormozdiari, F. et al. Colocalization of GWAS and eQTL Signals Detects Target Genes.
- 648 Am. J. Hum. Genet. 99, 1245–1260 (2016).
- 29. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
- stratification in genome-wide association studies. *Nat. Rev. Genet.* **11**, 459 (2010).
- 30. Mountjoy, E. et al. Open targets genetics: An open approach to systematically prioritize
- causal variants and genes at all published human GWAS trait-associated loci. *Nat. Genet.*
- 653 2020.09.16.299271 (2021) doi:10.1038/s41588-021-00945-5.
- 654 31. Ghoussaini, M. et al. Open Targets Genetics: Systematic identification of trait-associated
- genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**, D1311–
- 656 D1320 (2021).

- 32. Allen, R. J. et al. Genome-Wide Association Study of Susceptibility to Idiopathic
- 658 Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* **201**, 564–574 (2020).
- 33. Shrine, N. et al. New genetic signals for lung function highlight pathways and chronic
- obstructive pulmonary disease associations across multiple ancestries. *Nat. Genet.* 51,
- 661 481–493 (2019).
- 34. Sakornsakolpat, P. et al. Genetic landscape of chronic obstructive pulmonary disease
- identifies heterogeneous cell-type and phenotype associations. *Nat. Genet.* **51**, 494–505
- 664 (2019).
- 35. Olafsdottir, T. A. et al. Eighty-eight variants highlight the role of T cell regulation and
- airway remodeling in asthma pathogenesis. *Nat. Commun.* **11**, 393 (2020).
- 36. Yin, X. et al. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for
- systemic lupus erythematosus. *Ann. Rheum. Dis.* **80**, 632–640 (2021).
- 37. Law, P. J. et al. Genome-wide association analysis implicates dysregulation of immunity
- genes in chronic lymphocytic leukaemia. *Nat. Commun.* **8**, 14175 (2017).
- 38. Helgason, H. et al. Loss-of-function variants in ATM confer risk of gastric cancer. Nat.
- 672 *Genet.* **47**, 906–910 (2015).
- 39. Sandoval-Plata, G., Morgan, K. & Abhishek, A. Variants in urate transporters, ADH1B,
- 674 GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to

- gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians
- using data from the UK Biobank. *Ann. Rheum. Dis.* **80**, 1220–1226 (2021).
- 40. De Lange, K. M. et al. Genome-wide association study implicates immune activation of
- multiple integrin genes in inflammatory bowel disease. *Nat. Genet.* (2017)
- 679 doi:10.1038/ng.3760.
- 41. Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7,
- 681 eabh2169 (2021).
- 42. Castranova, V., Rabovsky, J., Tucker, J. H. & Miles, P. R. The alveolar type II epithelial
- cell: a multifunctional pneumocyte. *Toxicol. Appl. Pharmacol.* **93**, 472–483 (1988).
- 43. Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular
- 685 targets. *Nature* **595**, 107–113 (2021).
- 44. Katzourakis, A. COVID-19: endemic doesn't mean harmless. *Nature* **601**, 485 (2022).
- 45. Levin, A. A. Treating Disease at the RNA Level with Oligonucleotides. *N. Engl. J. Med.*
- **380**, 57–70 (2019).
- 46. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and
- antisense oligonucleotides. *Nat. Rev. Drug Discov.* **11**, 125–140 (2012).
- 691 47. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA
- 692 via targeted nanoparticles. *Nature* **464**, 1067–1070 (2010).

- 693 48. Segawa, K. et al. A sublethal ATP11A mutation associated with neurological
- deterioration causes aberrant phosphatidylcholine flipping in plasma membranes. J. Clin.
- 695 *Invest.* **131**, 148005 (2021).
- 49. Barkauskas, C. E. et al. Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest.
- **123**, 3025–3036 (2013).
- 698 50. Královičová, J. & Vořechovský, I. Position-Dependent Repression and Promotion of
- 699 DQB1 Intron 3 Splicing by GGGG Motifs. J. Immunol. 176, 2381–2388 (2006).
- 51. Hollingsworth, L. R. et al. DPP9 sequesters the C terminus of NLRP1 to repress
- 701 inflammasome activation. *Nature* **592**, 778–783 (2021).
- 52. Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19
- 703 pathology. *Nature* **606**, 585–593 (2022).
- 53. Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6/MUC1 in the
- 705 clinical management of interstitial lung diseases. *Respir. Investig.* **50**, 3–13 (2012).
- 54. Fowler, J. C., Teixeira, A. S., Vinall, L. E. & Swallow, D. M. Hypervariability of the
- membrane-associated mucin and cancer marker MUC1. *Hum. Genet.* **113**, 473–479
- 708 (2003).
- 709 55. Mukamel, R. E. et al. Protein-coding repeat polymorphisms strongly shape diverse human
- 710 phenotypes. *Science* **373**, 1499–1505 (2021).

- 56. Saeki, N. et al. A functional single nucleotide polymorphism in mucin 1, at chromosome
- 712 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 140, 892–
- 713 902 (2011).
- 57. Logsdon, G. A., Vollger, M. R. & Eichler, E. E. Long-read human genome sequencing
- and its applications. *Nat. Rev. Genet.* **21**, 597–614 (2020).
- 58. Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical
- applications: A SOMAmer-based, streamlined multiplex proteomic assay. *PLoS ONE* **6**,
- 718 (2011).
- 719 59. Rotival, M., Quach, H. & Quintana-Murci, L. Defining the genetic and evolutionary
- architecture of alternative splicing in response to infection. *Nat. Commun.* **10**, 1671
- 721 (2019).
- 60. Allen, R. J. et al. Genetic overlap between idiopathic pulmonary fibrosis and COVID-19.
- 723 Eur. Respir. J. **60**, 2103132 (2022).
- 724 61. Võsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic
- loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310
- 726 (2021).
- 727 62. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the
- 728 human phenome. *eLife* 7, e34408 (2018).

- 729 63. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-
- sample Mendelian randomization. *Genet. Epidemiol.* **40**, 597–608 (2016).
- 731 64. Burgess, S., Thompson, S. G., & CRP CHD Genetics Collaboration. Avoiding bias from
- weak instruments in Mendelian randomization studies. *Int. J. Epidemiol.* **40**, 755–764
- 733 (2011).

- 734 65. Vieira Braga, F. A. et al. A cellular census of human lungs identifies novel cell states in
- 735 health and in asthma. *Nat. Med.* **25**, 1153–1163 (2019).
- 736 66. Chen, J. et al. PBMC fixation and processing for Chromium single-cell RNA sequencing.
- 737 J. Transl. Med. 16, 198 (2018).
- 738 67. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-
- 739 19. *Nature* **600**, 472–477 (2021).